PTHS · Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Cap structure and valuation
| Cap structure | |
|---|---|
| SP | $26.40 |
| SO | 3.5M |
| Options | 1.5M |
| Warrants | 0.1M |
| FD SO | 5.1M |
| MC | $134.2M |
| Cash | $32.0M |
| Total debt | $49.6M |
| EV | $151.9M |
| TTM Multiples | |
|---|---|
| EV / Revenue | — |
| EV / EBITDA | — |
| MC / Net Income | — |
| EV / FCF | — |
| MC / FCF | — |
| Ownership & coverage | |
|---|---|
| Institutional | 35.6% |
| Insiders | 53.8% |
| # Institutions | 19 |
| Analysts | 7 |
| Consensus | Strong Buy |
| Avg target | $57.71 |
| Short % float | 1.6% |
| Days to cover | 1.27 |
MC = SP × FD SO. EV = MC + Debt − Cash. SP = previous yfinance close. Balance-sheet figures as of 2026-05-11. Multiples use TTM (sum of last 4 quarters); shown as "—" when the denominator is zero or negative, or when fewer than four quarters are reported — a partial sum is not a trailing twelve months. Ownership & coverage per Yahoo Finance as of 2026-07-13 — institutional % is 13F-based, so it can lag a quarter and exceed 100% on share-count timing. Short interest per FINRA bi-monthly reporting, as of 2026-06-29; the float denominator can be unreliable on tiny floats.
Financial statements
| 3/31/26 | 12/31/25 | 9/30/25 | 6/30/25 | |
|---|---|---|---|---|
| Total Revenue | 10.91 | 16.50 | 7.41 | — |
| Cost of Revenue | 1.67 | 1.67 | 2.32 | — |
| Gross Profit | 9.23 | 14.83 | 5.09 | — |
| Gross Margin % | 84.7% | 89.9% | 68.7% | — |
| SG&A | 21.10 | 18.47 | 19.63 | 1.11 |
| R&D | 0.19 | 0.37 | 0.14 | 0.51 |
| Operating Expense | 22.32 | 26.83 | 20.45 | — |
| Operating Income | (13.09) | (12.00) | (15.36) | (3.23) |
| Operating Income YoY % | (613.6%) | (558.1%) | (649.7%) | (83.1%) |
| Operating Margin % | (120.0%) | (72.7%) | (207.4%) | — |
| EBITDA | (12.62) | — | — | — |
| EBITDA Margin % | (115.7%) | — | — | — |
| Interest Expense | 2.35 | — | 1.35 | — |
| Other Income / (Expense) | 5.20 | (16.58) | — | — |
| Pretax Income | (10.24) | (28.59) | (16.70) | (3.45) |
| Tax Provision | 0.00 | (6.92) | (0.47) | — |
| Net Income | (10.24) | (21.66) | (16.24) | (3.45) |
| Net Margin % | (93.9%) | (131.3%) | (219.3%) | — |
| Diluted EPS | -$3.09 | -$8.08 | -$5.30 | -$5.38 |
| Basic EPS | -$3.09 | -$8.08 | -$5.30 | -$5.38 |
| Diluted Avg Shares | 3.3 | — | 3.1 | 0.6 |
| Basic Avg Shares | 3.3 | — | 3.1 | 0.6 |
| LTM | 12/31/25 | 12/31/24 | 12/31/23 | 12/31/22 | |
|---|---|---|---|---|---|
| Total Revenue | 27.70 | 16.80 | 0.00 | — | — |
| Revenue YoY % | 64.9% | — | — | — | — |
| Cost of Revenue | 5.66 | 3.99 | 0.00 | — | — |
| Gross Profit | — | 12.81 | — | — | — |
| Gross Margin % | — | 76.3% | — | — | — |
| SG&A | 60.31 | 42.45 | 6.39 | 2.74 | 1.10 |
| R&D | 1.22 | 1.23 | 1.18 | 2.58 | 0.39 |
| Operating Expense | — | 45.24 | — | — | — |
| Operating Income | (43.68) | (32.43) | (7.57) | (6.86) | (2.32) |
| Operating Income YoY % | (34.7%) | (328.3%) | (10.3%) | (196.0%) | — |
| Operating Margin % | (157.7%) | (193.1%) | — | — | — |
| EBITDA | (42.49) | (31.70) | (7.57) | — | — |
| EBITDA Margin % | (153.4%) | (188.8%) | — | — | — |
| Interest Expense | 5.36 | 3.01 | 0.58 | 0.31 | 0.14 |
| Other Income / (Expense) | (9.93) | (15.26) | — | — | — |
| Pretax Income | (58.98) | (50.71) | (7.96) | (7.38) | (2.46) |
| Tax Provision | (7.39) | (7.39) | 0.00 | — | — |
| Net Income | (51.59) | (43.32) | (7.96) | (7.38) | (2.46) |
| Net Margin % | (186.2%) | (257.9%) | — | — | — |
| Diluted EPS | -$21.85 | -$23.04 | -$14.27 | -$5.78 | — |
| Basic EPS | -$21.85 | -$23.04 | -$14.27 | -$5.78 | -$5.65 |
| Diluted Avg Shares | 3.3 | 1.9 | 0.6 | 1.3 | — |
| Basic Avg Shares | 3.3 | 1.9 | 0.6 | 1.3 | 0.4 |
| 3/31/26 | 12/31/25 | 9/30/25 | 6/30/25 | |
|---|---|---|---|---|
| Cash & Equivalents | 31.98 | 17.97 | 14.20 | 0.10 |
| Receivables | 11.70 | 8.86 | — | — |
| Inventory | 23.42 | 23.57 | 24.10 | — |
| Other Current Assets | 2.71 | 3.00 | 11.46 | 0.72 |
| Total Current Assets | 69.80 | 53.41 | 49.76 | 0.82 |
| Net PPE | 9.31 | 9.59 | 10.17 | — |
| Operating Lease ROU | 3.15 | 3.25 | 3.35 | — |
| Goodwill | 24.68 | 24.68 | 30.62 | — |
| Intangible Assets | 38.44 | 39.47 | 32.52 | — |
| Total Assets | 145.38 | 130.40 | 126.43 | 0.82 |
| Accounts Payable | 6.15 | 2.99 | 5.67 | — |
| Current Lease Liabilities | 0.64 | 0.64 | 0.63 | — |
| Other Current Liabilities | 18.22 | 22.37 | 18.47 | 7.32 |
| Total Current Liabilities | 25.00 | 25.99 | 24.77 | 7.32 |
| Long-term Lease Liabilities | 2.65 | 2.75 | — | — |
| Other Liabilities | 82.62 | 62.77 | 43.41 | — |
| Total Liabilities | 110.28 | 91.52 | 68.18 | 7.32 |
| Retained Earnings | (75.03) | (64.79) | (43.13) | (26.89) |
| Total Equity | 35.10 | 38.88 | 58.25 | (6.49) |
| LTM | 12/31/25 | 12/31/24 | 12/31/23 | 12/31/22 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 31.98 | 17.97 | 0.51 | 0.10 | 0.10 |
| Receivables | 11.70 | 8.86 | 0.00 | — | — |
| Inventory | 23.42 | 23.57 | 0.00 | — | — |
| Other Current Assets | 2.71 | 3.00 | 0.86 | — | — |
| Total Current Assets | 69.80 | 53.41 | 1.37 | 0.10 | 0.06 |
| Net PPE | 9.31 | 9.59 | 0.00 | — | — |
| Operating Lease ROU | 3.15 | 3.25 | 0.00 | — | — |
| Goodwill | 24.68 | 24.68 | 0.00 | — | — |
| Intangible Assets | 38.44 | 39.47 | 0.00 | — | — |
| Total Assets | 145.38 | 130.40 | 1.37 | 0.10 | 0.06 |
| Accounts Payable | 6.15 | 2.99 | 1.90 | — | — |
| Current Lease Liabilities | 0.64 | 0.64 | 0.00 | — | — |
| Other Current Liabilities | 18.22 | 22.37 | 2.19 | 6.54 | 3.76 |
| Total Current Liabilities | 25.00 | 25.99 | 4.08 | 6.54 | 3.76 |
| Long-term Lease Liabilities | 2.65 | 2.75 | 0.00 | — | — |
| Other Liabilities | 82.62 | 62.77 | — | — | — |
| Total Liabilities | 110.28 | 91.52 | 4.08 | 6.54 | 3.76 |
| Retained Earnings | (75.03) | (64.79) | (21.48) | (13.52) | (6.14) |
| Total Equity | 35.10 | 38.88 | (2.71) | (6.45) | (3.71) |
| 3/31/26 | 12/31/25 | 9/30/25 | 6/30/25 | |
|---|---|---|---|---|
| Net Income | (10.24) | (21.66) | (16.24) | (3.45) |
| D&A | 0.47 | — | — | — |
| Stock-Based Comp | 1.91 | 1.80 | 2.76 | 0.41 |
| Δ Working Cap & Other | (5.26) | 13.61 | (1.78) | 2.59 |
| Operating Cash Flow | (13.13) | (6.25) | (15.26) | (0.45) |
| CapEx | (0.19) | — | — | — |
| Other Investing | — | (8.00) | — | — |
| Investing Cash Flow | (0.19) | (8.00) | — | — |
| Other Financing | 27.52 | 18.02 | 26.69 | — |
| Financing Cash Flow | 27.52 | 18.02 | 26.69 | 0.38 |
| Free Cash Flow | (13.32) | — | — | — |
| LTM | 12/31/25 | 12/31/24 | 12/31/23 | 12/31/22 | |
|---|---|---|---|---|---|
| Net Income | (51.59) | (43.32) | (7.96) | (7.38) | (2.46) |
| D&A | 1.20 | 0.73 | 0.00 | — | — |
| Stock-Based Comp | 6.88 | 5.46 | 1.80 | 1.73 | 0.11 |
| Δ Working Cap & Other | 8.42 | 14.54 | 0.36 | 4.67 | 0.78 |
| Operating Cash Flow | (35.08) | (22.59) | (5.79) | (0.98) | (1.57) |
| CapEx | (0.29) | (0.10) | 0.00 | — | — |
| Other Investing | (5.14) | (5.14) | — | — | — |
| Investing Cash Flow | (5.43) | (5.24) | 0.00 | — | — |
| Debt Repayment | — | (0.84) | (0.21) | — | — |
| Stock Issuance | — | 0.00 | 5.97 | 0.26 | — |
| Stock Buyback | — | 0.00 | (0.07) | — | — |
| Other Financing | 72.61 | 46.18 | 0.53 | 0.77 | 1.62 |
| Financing Cash Flow | 72.61 | 45.34 | 6.21 | 1.02 | 1.62 |
| Free Cash Flow | (35.38) | (22.69) | (5.79) | — | — |
| 3/31/26 | 12/31/25 | 9/30/25 | 6/30/25 | |
|---|---|---|---|---|
| Current Ratio | 2.79 | 2.05 | 2.01 | 0.11 |
| Quick Ratio | 1.86 | 1.15 | 1.04 | — |
| Debt / Equity | 3.14 | 2.35 | 1.17 | -1.13 |
| EBITDA Margin % | (115.7%) | — | — | — |
| Working Capital | 44.80 | 27.42 | 24.99 | (6.49) |
| Net Debt | — | — | — | — |
| ROE % | (29.2%) | (55.7%) | (27.9%) | 53.1% |
| ROA % | (7.0%) | (16.6%) | (12.8%) | (419.2%) |
| LTM | 12/31/25 | 12/31/24 | 12/31/23 | 12/31/22 | |
|---|---|---|---|---|---|
| Current Ratio | 2.79 | 2.05 | 0.34 | 0.01 | 0.01 |
| Quick Ratio | 1.86 | 1.15 | 0.34 | — | — |
| Debt / Equity | 3.14 | 2.35 | -1.50 | -1.01 | -1.01 |
| EBITDA Margin % | (153.4%) | (188.8%) | — | — | — |
| Working Capital | 44.80 | 27.42 | (2.71) | (6.44) | (3.71) |
| Net Debt | — | — | — | — | — |
| ROE % | (147.0%) | (111.4%) | 293.1% | 114.5% | 66.3% |
| ROA % | (35.5%) | (33.2%) | (581.1%) | (7657.1%) | (4464.2%) |
Insider activity (last 2 years)
| Date Filed | Reporter | Relationship | Trans. Date | Code | Shares | Price | Total Value |
|---|---|---|---|---|---|---|---|
| 2026-06-15 | Davis Todd C | Director | 2026-06-11 | P | 35,445 | $27.80 | $985,534 |
| 2026-06-15 | Davis Todd C | Director | 2026-06-11 | P | 503 | $28.73 | $14,449 |
| 2026-05-26 | Francis Knuettel II | Officer (CFO, Treas & Secty) | 2026-05-22 | D | (13,947) | — | $-0 |
| 2026-05-26 | Francis Knuettel II | Officer (CFO, Treas & Secty) | 2026-05-22 | S | (1,500) | $26.84 | -$40,265 |
| 2026-05-26 | Francis Knuettel II | Officer (CFO, Treas & Secty) | 2026-05-22 | A | 59,500 | — | $0 |
| 2026-05-26 | Francis Knuettel II | Officer (CFO, Treas & Secty) | 2026-05-22 | D | (42,500) | — | $-0 |
| 2026-05-18 | Friedberg Ezra M | Director | 2026-05-14 | F | (144) | $27.01 | -$3,889 |
| 2026-04-06 | Malamut Richard | Director | 2026-04-02 | S | (310) | $20.51 | -$6,359 |
| 2026-04-06 | Malamut Richard | Director | 2026-04-02 | S | (280) | $21.36 | -$5,981 |
| 2026-04-06 | Friedberg Ezra M | Director | 2026-04-02 | S | (293) | $20.51 | -$6,010 |
| 2026-04-06 | Friedberg Ezra M | Director | 2026-04-02 | S | (265) | $21.36 | -$5,661 |
| 2026-04-06 | Pauls Matthew | Director | 2026-04-02 | S | (415) | $20.52 | -$8,514 |
| 2026-04-06 | Pauls Matthew | Director | 2026-04-02 | S | (371) | $21.36 | -$7,926 |
| 2026-04-06 | Greenleaf Peter | Director | 2026-04-02 | S | (420) | $20.52 | -$8,616 |
| 2026-04-06 | Greenleaf Peter | Director | 2026-04-02 | S | (377) | $21.36 | -$8,053 |
| 2026-04-01 | Malamut Richard | Director | 2025-11-13 | A | 2,454 | — | $0 |
| 2026-04-01 | Friedberg Ezra M | Director | 2025-07-02 | A | 19,108 | — | $0 |
| 2026-04-01 | Davis Todd C | Director | 2025-07-02 | A | 19,108 | — | $0 |
| 2026-04-01 | Malamut Richard | Director | 2025-07-02 | A | 19,108 | — | $0 |
| 2026-04-01 | Plesha Scott M. | Director, Officer (CEO and President) | 2025-07-02 | A | 83,678 | — | $0 |
| 2026-04-01 | Greenleaf Peter | Director | 2025-07-02 | A | 25,478 | — | $0 |
| 2026-04-01 | Pauls Matthew | Director | 2025-07-02 | A | 25,478 | — | $0 |
| 2026-04-01 | Rangarao Sai | Officer (Chief Commercial Officer) | 2025-07-02 | A | 30,518 | — | $0 |
| 2026-04-01 | Baxter Richard B | Director | 2025-07-02 | A | 19,108 | — | $0 |
| 2026-04-01 | Francis Knuettel II | Officer (CFO, Treas & Secty) | 2025-07-02 | A | 33,472 | — | $0 |
| 2026-04-01 | Friedberg Ezra M | Director | 2024-11-13 | A | 2,454 | — | $0 |
| 2026-04-01 | Davis Todd C | Director | 2024-11-13 | A | 4,961 | — | $0 |
| 2026-04-01 | Friedberg Ezra M | Director | 2024-06-14 | A | 6,450 | — | $0 |
| 2026-04-01 | Davis Todd C | Director | 2024-06-14 | A | 12,900 | — | $0 |
| 2026-04-01 | Malamut Richard | Director | 2024-06-14 | A | 6,450 | — | $0 |
| 2025-12-29 | Einhorn Andrew J. | Director | 2025-12-23 | A | 12,000 | — | $0 |
| 2025-12-19 | LIGAND PHARMACEUTICALS INC | Director, 10% Owner | 2025-12-17 | D | 0 | — | $-0 |
| 2025-12-19 | LIGAND PHARMACEUTICALS INC | Director, 10% Owner | 2025-12-17 | A | 0 | — | $0 |
| 2025-12-12 | Pauls Matthew | Director | 2025-12-10 | G | (9,542) | — | $-0 |
| 2025-12-12 | Pauls Matthew | Director | 2025-10-02 | M | 2,123 | — | $0 |
| 2025-12-12 | Pauls Matthew | Director | 2025-10-02 | M | (2,123) | — | $-0 |
| 2025-12-12 | Pauls Matthew | Director | 2025-07-02 | M | 8,493 | — | $0 |
| 2025-12-12 | Pauls Matthew | Director | 2025-07-02 | M | (8,493) | — | $-0 |
| 2025-11-26 | Friedberg Ezra M | Director | 2025-11-25 | S | (5,999) | $28.00 | -$167,972 |
| 2025-11-26 | Friedberg Ezra M | Director | 2025-11-25 | S | (2,000) | $28.14 | -$56,270 |
| 2025-11-26 | Friedberg Ezra M | Director | 2025-11-25 | S | (1) | $28.50 | -$28 |
| 2025-11-26 | Friedberg Ezra M | Director | 2025-11-25 | S | (2,000) | $28.00 | -$56,010 |
| 2025-11-10 | LIGAND PHARMACEUTICALS INC | Director, 10% Owner | 2025-11-06 | A | 0 | $9,000,000.00 | $0 |
| 2025-07-23 | Plesha Scott M. | Director, Officer (CEO and President) | 2025-07-02 | A | 83,678 | — | $0 |
| 2025-07-23 | Plesha Scott M. | Director, Officer (CEO and President) | 2025-07-02 | A | 255,000 | — | $0 |
| 2025-07-21 | Rangarao Sai | Officer (Chief Commercial Officer) | 2025-07-02 | A | 30,518 | — | $0 |
| 2025-07-21 | Rangarao Sai | Officer (Chief Commercial Officer) | 2025-07-02 | A | 93,000 | — | $0 |
| 2025-07-07 | Baxter Richard B | Director | 2025-07-02 | A | 19,108 | — | $0 |
| 2025-07-07 | Baxter Richard B | Director | 2025-07-02 | A | 58,230 | — | $0 |
| 2025-07-07 | Greenleaf Peter | Director | 2025-07-02 | A | 25,478 | — | $0 |
| 2025-07-07 | Greenleaf Peter | Director | 2025-07-02 | A | 77,640 | — | $0 |
| 2025-07-07 | Pauls Matthew | Director | 2025-07-02 | A | 25,478 | — | $0 |
| 2025-07-07 | Pauls Matthew | Director | 2025-07-02 | A | 77,640 | — | $0 |
| 2025-07-07 | Francis Knuettel II | Officer (CFO, Treas & Secty) | 2025-07-02 | A | 33,472 | — | $0 |
| 2025-07-07 | Francis Knuettel II | Officer (CFO, Treas & Secty) | 2025-07-02 | A | 102,000 | — | $0 |
| 2025-07-07 | Davis Todd C | Director | 2025-07-02 | A | 19,108 | — | $0 |
| 2025-07-07 | Davis Todd C | Director | 2025-07-02 | A | 58,230 | — | $0 |
| 2025-07-07 | Friedberg Ezra M | Director | 2025-07-02 | A | 19,108 | — | $0 |
| 2025-07-07 | Friedberg Ezra M | Director | 2025-07-02 | A | 58,230 | — | $0 |
| 2025-07-07 | Malamut Richard | Director | 2025-07-02 | A | 19,108 | — | $0 |
| 2025-07-07 | Malamut Richard | Director | 2025-07-02 | A | 58,230 | — | $0 |
| 2025-07-03 | Friedberg Ezra M | Director | 2025-07-01 | C | 40,000 | $10.00 | $400,000 |
| 2025-07-03 | Friedberg Ezra M | Director | 2025-07-01 | C | 40,000 | $10.00 | $400,000 |
| 2025-07-03 | Friedberg Ezra M | Director | 2025-07-01 | P | 40,000 | — | $0 |
| 2025-07-03 | Friedberg Ezra M | Director | 2025-07-01 | P | 40,000 | — | $0 |
| 2025-07-03 | Friedberg Ezra M | Director | 2025-07-01 | C | (40,000) | — | $-0 |
| 2025-07-03 | Friedberg Ezra M | Director | 2025-07-01 | C | (40,000) | — | $-0 |
| 2025-07-03 | Francis Knuettel II | Officer (Chief Financial Officer) | 2025-07-01 | C | 10,000 | $10.00 | $100,000 |
| 2025-07-03 | Francis Knuettel II | Officer (Chief Financial Officer) | 2025-07-01 | J | 10,000 | — | $0 |
| 2025-07-03 | Francis Knuettel II | Officer (Chief Financial Officer) | 2025-07-01 | C | (10,000) | — | $-0 |
| 2025-07-03 | Davis Todd C | Director, 10% Owner | 2025-07-01 | C | 1,500,000 | $10.00 | $15,000,000 |
| 2025-07-03 | Davis Todd C | Director, 10% Owner | 2025-07-01 | C | (15,000) | — | $-0 |
| 2025-07-03 | Davis Todd C | Director, 10% Owner | 2025-07-01 | J | 31,278 | — | $0 |
| 2025-07-03 | LIGAND PHARMACEUTICALS INC | 10% Owner | 2025-07-01 | C | 1,500,000 | $10.00 | $15,000,000 |
| 2025-07-03 | LIGAND PHARMACEUTICALS INC | 10% Owner | 2025-07-01 | C | (15,000) | — | $-0 |
| 2025-07-03 | LIGAND PHARMACEUTICALS INC | 10% Owner | 2025-07-01 | J | 31,278 | — | $0 |
| 2025-04-15 | Simmons Chia-Lin | Director | 2025-04-11 | A | 25,000 | — | $0 |
| 2025-04-15 | Francis Knuettel II | Officer (CEO, Pres., CFO, Treas & Secty) | 2025-04-11 | A | 53,988 | — | $0 |
| 2024-11-15 | Davis Todd C | Director | 2024-11-13 | A | 49,605 | — | $0 |
| 2024-11-15 | Malamut Richard | Director | 2024-11-13 | A | 24,533 | — | $0 |
| 2024-11-15 | Friedberg Ezra M | Director | 2024-11-13 | A | 24,533 | — | $0 |
| 2024-09-16 | Francis Knuettel II | Officer (CEO, Pres., CFO, Treas & Secty) | 2024-09-13 | P | 3,500 | $0.97 | $3,395 |
| 2024-09-16 | Malamut Richard | Director | 2024-09-12 | P | 10,400 | $0.94 | $9,825 |
| 2024-09-16 | Francis Knuettel II | Officer (CEO, Pres., CFO, Treas & Secty) | 2024-09-12 | P | 1,700 | $0.97 | $1,649 |
| 2024-09-12 | Francis Knuettel II | Officer (CEO, Pres., CFO, Treas & Secty) | 2024-09-11 | P | 5,500 | $0.94 | $5,170 |
| 2024-09-12 | Francis Knuettel II | Officer (CEO, Pres., CFO, Treas & Secty) | 2024-09-10 | P | 6,500 | $0.89 | $5,785 |
| 2024-07-02 | Francis Knuettel II | Officer (CEO, Pres., CFO Treas & Secty) | 2024-06-28 | G | (5,000) | — | $-0 |
| 2024-07-02 | Francis Knuettel II | Officer (CEO, Pres., CFO Treas & Secty) | 2024-06-28 | G | (15,000) | — | $-0 |
| 2024-06-18 | Simmons Chia-Lin | Director | 2024-06-14 | A | 90,000 | — | $0 |
| 2024-06-18 | Lang Eric | Officer (Chief Medical Officer) | 2024-06-14 | A | 130,000 | — | $0 |
| 2024-06-18 | Friedberg Ezra M | Director | 2024-06-14 | A | 64,498 | — | $0 |
| 2024-06-18 | Malamut Richard | Director | 2024-06-14 | A | 64,498 | — | $0 |
| 2024-06-18 | Francis Knuettel II | Officer (CEO, Pres., CFO Treas & Secty) | 2024-06-14 | A | 27,778 | — | $0 |
| 2024-06-18 | Francis Knuettel II | Officer (CEO, Pres., CFO Treas & Secty) | 2024-06-14 | A | 324,000 | — | $0 |
| 2024-06-18 | Davis Todd C | Director | 2024-06-14 | A | 128,977 | — | $0 |
| 2024-06-18 | Francis Knuettel II | Officer (CEO, Pres., CFO Treas & Secty) | 2024-02-21 | A | 2,778 | — | $0 |